Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Flågeng, Marianne Hauglid ^a,b   Knappskog, Stian ^a,b   Haynes, Ben P ^c   Lønning, Per Eystein ^a,b   Mellgren, Gunnar ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTRADIOL; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; VASCULOTROPIN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; DOWN REGULATION; ESTRADIOL BLOOD LEVEL; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE DOSAGE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MASTECTOMY; POSTMENOPAUSE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BREAST; BREAST NEOPLASMS; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3;

EID: 84882779627     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074618     Document Type: Article

References (61)

1. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874. doi:10.1073/pnas.191367098. PubMed: 11553815.
2. Johnston S, Pippen J Jr., Pivot X, Lichinitser M, Sadeghi S, et al. (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27: 5538-5546. doi:10.1200/JCO.2009.23.3734. PubMed: 19786658.
3. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, et al. (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27: 5529-5537. doi:10.1200/JCO.2008.20.6847. PubMed: 19786670.
4. Arpino G, Wiechmann L, Osborne CK, Schiff R, (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233. PubMed: 18216219.
5. Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, et al. (2010) Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 16: 1486-1497. doi:10.1158/1078-0432.CCR-09-1764. PubMed: 20179226.
6. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, et al. (2003) Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278: 30458-30468. doi:10.1074/jbc.M305226200. PubMed: 12775708.
7. Flågeng MH, Moi LL, Dixon JM, Geisler J, Lien EA, et al. (2009) Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer 101: 1253-1260. doi:10.1038/sj.bjc.6605324. PubMed: 19755984.
8. Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE, et al. (2011) Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin beta1. Breast Cancer Res BCR 13: R29. doi:10.1186/bcr2848.
9. Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K, (2003) Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. J Steroid Biochem Mol Biol 85: 33-47. doi:10.1016/S0960-0760(03)00139-0. PubMed: 12798355.
10. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, et al. (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16: 1340-1349.
11. Quénel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, et al. (1995) The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 35: 283-291. doi:10.1007/BF00665980. PubMed: 7579499.
12. Tagliabue E, Ménard S, Robertson JF, Harris L, (1999) c-erbB-2 expression in primary breast cancer. Int J Biol Markers 14: 16-26. PubMed: 10367245.
13. Purdie CA, Baker L, Ashfield A, Chatterjee S, Jordan LB, et al. (2010) Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br J Cancer 103: 475-481. doi:10.1038/sj.bjc.6605799. PubMed: 20664587.
14. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, et al. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808-3816. PubMed: 11559718.
15. Pinhel I, Hills M, Drury S, Salter J, Sumo G, et al. (2012) ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res 14: R46. doi:10.1186/bcr3145. PubMed: 22417870.
16. Larsen MS, Bjerre K, Lykkesfeldt AE, Giobbie-Hurder A, Laenkholm AV, et al. (2012) Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. Breast 21: 662-668. doi:10.1016/j.breast.2012.07.005. PubMed: 22854050.
17. Haynes BP, Straume AH, Geisler J, A'Hern R, Helle H, et al. (2010) Intratumoral estrogen disposition in breast cancer. Clin Cancer Res 16: 1790-1801. doi:10.1158/1078-0432.CCR-09-2481. PubMed: 20215536.
18. Lønning PE, Helle H, Duong NK, Ekse D, Aas T, et al. (2009) Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 117: 31-41. doi:10.1016/j.jsbmb.2009.06.005. PubMed: 19591931.
19. Geisler J, Berntsen H, Lonning PE, (2000) A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. J Steroid Biochem Mol Biol 72: 259-264. doi:10.1016/S0960-0760(00)00036-4. PubMed: 10822015.
20. Geisler J, Ekse D, Helle H, Duong NK, Lønning PE, (2008) An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. J Steroid Biochem Mol Biol 109: 90-95. doi:10.1016/j.jsbmb.2007.12.011. PubMed: 18242079.
21. Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, et al. (2005) Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res 65: 5380-5389. doi:10.1158/0008-5472.CAN-04-4502. PubMed: 15958587.
22. Johnston SR, Martin LA, Leary A, Head J, Dowsett M, (2007) Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J Steroid Biochem Mol Biol 106: 180-186. doi:10.1016/j.jsbmb.2007.05.019. PubMed: 17624764.
23. Masri S, Phung S, Wang X, Chen S, (2010) Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines. J Steroid Biochem Mol Biol 118: 277-282. doi:10.1016/j.jsbmb.2009.10.011. PubMed: 19897035.
24. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, et al. (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23: 2469-2476. doi:10.1200/JCO.2005.01.172. PubMed: 15753463.
25. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, et al. (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11: 4741-4748. doi:10.1158/1078-0432.CCR-04-2569. PubMed: 16000569.
26. De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, et al. (2003) Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9: 1039-1046. PubMed: 12631604.
27. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, et al. (2006) Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17: 818-826. doi:10.1093/annonc/mdl016. PubMed: 16497822.
28. Bates NP, Hurst HC, (1997) An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene 15: 473-481. doi:10.1038/sj.onc.1201368. PubMed: 9242384.
29. Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, et al. (2006) Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer 13 (Suppl 1):: S77-S88. doi:10.1677/erc.1.01274. PubMed: 17259561.
30. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, et al. (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456: 663-666. doi:10.1038/nature07483. PubMed: 19005469.
31. Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC, (2000) Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 19: 490-497. doi:10.1038/sj.onc.1203416. PubMed: 10698518.
32. Yarden RI, Wilson MA, Chrysogelos SA, (2001) Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem Supplement Suppl 36: 232-246. PubMed: 11455588.
33. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, et al. (2009) Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 114: 263-275. doi:10.1007/s10549-008-0011-8. PubMed: 18409071.
34. Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, et al. (2010) Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 126: 545-562. doi:10.1002/ijc.24750. PubMed: 19609946.
35. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, et al. (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28: 1124-1130. doi:10.1200/JCO.2008.21.4437. PubMed: 20124187.
36. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, et al. (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366: 109-119. doi:10.1056/NEJMoa1113216. PubMed: 22149875.
37. Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, et al. (2010) Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 16: 1904-1914. doi:10.1158/1078-0432.CCR-09-2282. PubMed: 20215537.
38. Dowsett M, Leary A, Evans A, A'Hern R, Bliss J, et al. (2012) Prediction of antiproliferative response to lapatinib by HER3 in an exploratory analysis of HER2-non-amplified (HER2-) breast cancer in the MAPLE presurgical study (CRUK E/06/039). San Antonio, Texas; US.
39. Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, et al. (2010) The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol/Hematol 74: 73-78. doi:10.1016/j.critrevonc.2009.04.011. PubMed: 19481955.
40. Keshamouni VG, Mattingly RR, Reddy KB, (2002) Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. J Biol Chem 277: 22558-22565. doi:10.1074/jbc.M202351200. PubMed: 11960991.
41. Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, et al. (2009) Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling. Mol Cancer Res 7: 1882-1892. PubMed: 19861407.
42. Revillion F, Pawlowski V, Lhotellier V, Louchez MM, Peyrat JP, (2003) mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen. Anticancer Res 23: 1455-1460. PubMed: 12820409.
43. Russell KS, Hung MC, (1992) Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 52: 6624-6629. PubMed: 1358436.
44. Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, et al. (2003) Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 17: 818-830. doi:10.1210/me.2002-0330. PubMed: 12554767.
45. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, et al. (2006) Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res 66: 7991-7998. doi:10.1158/0008-5472.CAN-05-4397. PubMed: 16912174.
46. Citri A, Skaria KB, Yarden Y, (2003) The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284: 54-65. doi:10.1016/S0014-4827(02)00101-5. PubMed: 12648465.
47. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, et al. (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68: 5878-5887. doi:10.1158/0008-5472.CAN-08-0380. PubMed: 18632642.
48. Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, et al. (2008) Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer 99: 1775-1785. doi:10.1038/sj.bjc.6604769. PubMed: 18985033.
49. Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, et al. (2008) Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 10: R2. doi:10.1186/bcr1886. PubMed: 18182100.
50. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM, (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200: 290-297. doi:10.1002/path.1370. PubMed: 12845624.
51. Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, et al. (2010) HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Ann Surg 251: 1107-1116. doi:10.1097/SLA.0b013e3181dbb77e. PubMed: 20485140.
52. Sheng Q, Liu X, Fleming E, Yuan K, Piao H, et al. (2010) An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17: 298-310. doi:10.1016/j.ccr.2009.12.047. PubMed: 20227043.
53. Wilson TR, Lee DY, Berry L, Shames DS, Settleman J, (2011) Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 20: 158-172. doi:10.1016/j.ccr.2011.07.011. PubMed: 21840482.
54. Chua YL, Ito Y, Pole JC, Newman S, Chin SF, et al. (2009) The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. Oncogene 28: 4041-4052. doi:10.1038/onc.2009.259. PubMed: 19802002.
55. deFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL, (2000) Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 87: 487-498. doi:10.1002/1097-0215(20000815)87:4. PubMed: 10918187.
56. Salvatori L, Caporuscio F, Coroniti G, Starace G, Frati L, et al. (2009) Down-regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells. J Cell Physiol 220: 35-44. doi:10.1002/jcp.21724. PubMed: 19347870.
57. Koenders PG, Beex LV, Geurts-Moespot A, Heuvel JJ, Kienhuis CB, et al. (1991) Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res 51: 4544-4548. PubMed: 1873798.
58. Salvatori L, Ravenna L, Felli MP, Cardillo MR, Russo MA, et al. (2000) Identification of an estrogen-mediated deoxyribonucleic acid-binding independent transactivation pathway on the epidermal growth factor receptor gene promoter. Endocrinology 141: 2266-2274. doi:10.1210/en.141.6.2266. PubMed: 10830317.
59. Wilson MA, Chrysogelos SA, (2002) Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells. J Cell Biochem 85: 601-614. doi:10.1002/jcb.10168. PubMed: 11968000.
60. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, et al. (2005) EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18: 1027-1033. doi:10.1038/modpathol.3800438. PubMed: 15920544.
61. Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, et al. (2008) HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14: 7861-7870. doi:10.1158/1078-0432.CCR-08-1056. PubMed: 19047115.